BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan
· Delayed Price · Currency is TWD 26.25
+0.05 (0.19%)
Apr 24, 2025, 1:17 PM CST
BioGend Therapeutics Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Net Income | -116.47 | -156.33 | -184.46 | -138.49 | -145.59 | Upgrade
|
| Depreciation & Amortization | 51.19 | 55.02 | 53.18 | 28.19 | 19.19 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | - | 0.48 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | -26.7 | - | Upgrade
|
| Loss (Gain) on Equity Investments | 2.46 | -10.34 | - | 11.35 | 14.24 | Upgrade
|
| Stock-Based Compensation | 3.64 | - | - | - | - | Upgrade
|
| Other Operating Activities | -13.02 | -13.1 | -29.26 | -5.81 | -0.35 | Upgrade
|
| Change in Accounts Receivable | -20.67 | -15.42 | -6.22 | -4.72 | 0.03 | Upgrade
|
| Change in Inventory | 0.58 | -11.65 | 4.13 | 1.38 | -7.9 | Upgrade
|
| Change in Accounts Payable | 2.06 | 0.08 | 1.6 | -0.88 | 0.3 | Upgrade
|
| Change in Unearned Revenue | -2.5 | - | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | -16.17 | 13.02 | 2.23 | -1.12 | 2.48 | Upgrade
|
| Operating Cash Flow | -98.91 | -138.72 | -168.78 | -136.8 | -117.13 | Upgrade
|
| Capital Expenditures | -0.65 | -26.04 | -18.18 | -0.67 | -0.2 | Upgrade
|
| Cash Acquisitions | - | - | - | 26.41 | - | Upgrade
|
| Sale (Purchase) of Intangibles | - | 0.32 | - | - | - | Upgrade
|
| Investment in Securities | -6.24 | -64 | 223.2 | -159.97 | -112.99 | Upgrade
|
| Other Investing Activities | -1.31 | 0.08 | -3.32 | -0.04 | -0.32 | Upgrade
|
| Investing Cash Flow | -8.2 | -89.64 | 201.7 | -134.27 | -113.51 | Upgrade
|
| Long-Term Debt Repaid | -3.64 | -3.58 | -4.81 | -1.78 | - | Upgrade
|
| Net Debt Issued (Repaid) | -3.64 | -3.58 | -4.81 | -1.78 | - | Upgrade
|
| Issuance of Common Stock | - | 400 | - | 289.63 | 260 | Upgrade
|
| Other Financing Activities | - | - | - | - | 0.9 | Upgrade
|
| Financing Cash Flow | -3.64 | 396.42 | -4.81 | 287.85 | 260.9 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.74 | -1.19 | -0.79 | -0.49 | - | Upgrade
|
| Net Cash Flow | -111.49 | 166.87 | 27.32 | 16.28 | 30.27 | Upgrade
|
| Free Cash Flow | -99.56 | -164.76 | -186.96 | -137.47 | -117.33 | Upgrade
|
| Free Cash Flow Margin | -59.38% | -149.91% | -594.54% | -1483.13% | -8422.90% | Upgrade
|
| Free Cash Flow Per Share | -0.81 | -1.37 | -1.81 | -1.36 | -1.34 | Upgrade
|
| Cash Interest Paid | 0.22 | 0.26 | 0.09 | 0.02 | 0.01 | Upgrade
|
| Cash Income Tax Paid | 0.5 | 0.2 | -0.18 | - | 0.12 | Upgrade
|
| Levered Free Cash Flow | -57.11 | -95.39 | -98.09 | -83.82 | -69.96 | Upgrade
|
| Unlevered Free Cash Flow | -56.97 | -95.23 | -98.04 | -83.81 | -69.96 | Upgrade
|
| Change in Net Working Capital | 34.73 | 14.19 | -3.97 | 8.63 | 5.44 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.